Why the study?
Do Class III antiarrhythmic drugs (amiodarone and sotalol) improve rhythm and rate control in patients with atrial fibrillation?
Do Class III antiarrhythmic drugs (amiodarone and sotalol) improve rhythm and rate control in patients with atrial fibrillation?
Answers are grounded in this paper and cite their sources.
Amiodarone and sotalol are effective for rhythm and rate control in atrial fibrillation, with amiodarone offering specific advantages in patients with concomitant heart failure.
In summary, the Class III antiarrhythmic agents amiodarone and sotalol are effective in restoring sinus rhythm in patients with chronic atrial fibrillation with a higher effectiveness of amiodarone. Both agents successfully prevent recurrent episodes of atrial fibrillation after electrical cardioversion and both can control heart rate in persistent atrial fibrillation. Amiodarone appears to be particularly suitable in patients with atrial fibrillation and concomitant congestive heart failure because it lacks clinically relevant negative inotropic activity. Both substances are also effective in controlling ventricular arrhythmias that are frequently present in patients with atrial fibrillation. Finally, both drugs possess antiadrenergic activity, which makes the substances particularly attractive in patients with coronary heart disease as the underlying cause of atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Stefan H. Hohnloser (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: